<DOC>
	<DOCNO>NCT03071133</DOCNO>
	<brief_summary>An observational , postmarketing commitment follow marketing authorization DCV Trio therapy Japan .</brief_summary>
	<brief_title>Real-world Incidence Proportion Hepatic Toxicity All Adverse Drug Reactions ( ADRs ) Japanese Patients Receiving Daclatasvir ( DCV ) Trio Therapy</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>Patients initiate treatment DCV Trio therapy approve indication , dosage , administration Patients use DCV Trio label</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>